# Biomarkers of Androgen Response and Resistance In Evolution During a Rising PSA

> **NCT02429193** · PHASE2 · COMPLETED · sponsor: **University Health Network, Toronto** · enrollment: 16 (estimated)

## Conditions studied

- Castration-resistant Prostate Cancer

## Interventions

- **DRUG:** Abiraterone + prednisone
- **DRUG:** Enzalutamide

## Key facts

- **NCT ID:** NCT02429193
- **Lead sponsor:** University Health Network, Toronto
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-03
- **Primary completion:** 2019-09-01
- **Final completion:** 2019-09-01
- **Target enrollment:** 16 (ESTIMATED)
- **Last updated:** 2020-01-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02429193

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02429193, "Biomarkers of Androgen Response and Resistance In Evolution During a Rising PSA". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02429193. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*